Efficacy and Safety of <b><i>ALK</i></b> Tyrosine Kinase Inhibitors in Elderly Patients with Advanced <b><i>ALK</i></b>-Positive Non-Small Cell Lung Cancer: Findings from the Real-Life Cohort

克里唑蒂尼 铈替尼 医学 间变性淋巴瘤激酶 内科学 肺癌 胃肠病学 恶性胸腔积液
作者
Aseel Bedas,Nir Peled,Natalie Maimon Rabinovich,Moshe Mishaeli,Tzippy Shochat,Alona Zer,Ofer Rotem,Aaron M. Allen,Jair Bar,Elizabeth Dudnik
出处
期刊:Oncology Research and Treatment [S. Karger AG]
卷期号:42 (5): 275-282 被引量:13
标识
DOI:10.1159/000499086
摘要

Little is known regarding the anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) efficacy and safety in the elderly.Consecutive patients (n = 53) with ALK-positive advanced non-small cell lung cancer treated with an ALK TKI were identified through internal databases of three cancer centers and divided into groups A (< 65 years old; n = 34) and B (≥65 years old; n = 19). Progression-free survival (PFS), ALK TKI safety and overall survival (OS) were assessed. Uni- and multivariate PFS and OS analyses were performed.Crizotinib, ceritinib, and alectinib were administered in 94 and 100%, 35 and 31%, 38 and 52% of patients in groups A and B, respectively. The median PFS (months) was 5.4 (95% CI, 3.4-12.4) and 5.6 (95% CI, 2.5-14.7) with crizotinib (log-rank 0.0009, p = 0.9), 4.7 (95% CI, 1.0-11.5) and 23.0 (95% CI, 0.8-27.7) with ceritinib (log-rank 0.44, p = 0.5), and 21.2 (95% CI, 1.2 to not reached, NR) and 5.6 (95% CI, 0.5 to NR) with alectinib (log-rank 0.53, p = 0.5) in groups A and B, respectively. The median OS (months) comprised 29.8 (95% CI, 21.0 to NR) and 25.1 (95% CI, 10.8-53.6) in groups A and B, respectively (log-rank 0.57, p = 0.4). Age affected neither PFS nor OS. 19 and 37%, 50 and 40%, and 0 and 0% of patients in groups A and B, treated with crizotinib, ceritinib, and alectinib, respectively, developed high-grade adverse events. The treatment discontinuation rate was 9 and 21%, 16 and 60%, 0 and 0% with crizotinib, ceritinib, and alectinib in groups A and B, respectively.In the elderly, crizotinib, ceritinib, and alectinib treatments are associated with similar efficacy but different safety profiles; alectinib is associated with a lower rate of high-grade adverse events and a lower treatment discontinuation rate.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
田李君完成签到,获得积分10
刚刚
1秒前
寻道图强应助嘚嘚采纳,获得30
1秒前
1秒前
江子川完成签到,获得积分10
1秒前
香蕉乐菱完成签到 ,获得积分10
2秒前
orange9发布了新的文献求助10
2秒前
黑钻完成签到,获得积分10
3秒前
8R60d8应助闪闪天晴采纳,获得10
3秒前
阳光女孩完成签到,获得积分10
3秒前
相知发布了新的文献求助10
3秒前
HHHHHHH完成签到,获得积分10
3秒前
4秒前
4秒前
monica发布了新的文献求助10
4秒前
我不是很帅完成签到,获得积分10
4秒前
5秒前
科研小白发布了新的文献求助10
5秒前
Wait完成签到,获得积分10
5秒前
岩下松风发布了新的文献求助10
5秒前
Aspirin完成签到,获得积分10
5秒前
麦麦欧巴完成签到,获得积分10
6秒前
6秒前
CLN完成签到,获得积分10
6秒前
6秒前
彭于晏应助董小贱采纳,获得10
7秒前
7秒前
协和_子鱼完成签到,获得积分0
7秒前
小刺猬完成签到,获得积分10
8秒前
lzj001983完成签到,获得积分10
8秒前
微风完成签到,获得积分10
8秒前
jiajia发布了新的文献求助10
8秒前
8秒前
9秒前
9秒前
gxmu6322完成签到,获得积分10
9秒前
麦麦欧巴发布了新的文献求助10
9秒前
10秒前
收醉人完成签到,获得积分10
10秒前
11秒前
高分求助中
Licensing Deals in Pharmaceuticals 2019-2024 3000
Effect of reactor temperature on FCC yield 2000
Very-high-order BVD Schemes Using β-variable THINC Method 1020
Impiego dell’associazione acetazolamide/pentossifillina nel trattamento dell’ipoacusia improvvisa idiopatica in pazienti affetti da glaucoma cronico 900
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 800
錢鍾書楊絳親友書札 600
Geochemistry, 2nd Edition 地球化学经典教科书第二版,不要epub版本 431
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3294979
求助须知:如何正确求助?哪些是违规求助? 2931033
关于积分的说明 8449725
捐赠科研通 2603561
什么是DOI,文献DOI怎么找? 1421144
科研通“疑难数据库(出版商)”最低求助积分说明 660825
邀请新用户注册赠送积分活动 643654